RKV.V Rakovina Therapeutics Inc

Healthcare Biotechnology TSX Venture Exchange
0.2000 CAD
Close of Nov 7, 2026
0.0850 0.3200
Market cap
CAD 4.88M
P/E
-
P/B
20.43x
ROE
-
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.

Is RKV.V undervalued?

Graham number

The Graham number of Rakovina Therapeutics Inc cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Rakovina Therapeutics Inc fundamental analysis

No fundamental analysis for Rakovina Therapeutics Inc yet.

Rakovina Therapeutics Inc stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Rakovina Therapeutics Inc

Rakovina Therapeutics Inc., a biopharmaceutical research company, engages in the research and development of cancer treatments that target DNA-damage response systems. It develops kt-2000 series, which are patented class of oral, small molecule PARP inhibitors with established in vitro and in vivo proof of concept; kt-3000 series drug candidates, which are bi-functional targeted small molecules designed to inhibit both PARP and histone deacetylase; and kt-4000 series, which …

Full company profile